Cancer-Associated Fibroblasts Promote Angiogenesis of Hepatocellular Carcinoma by VEGF-Mediated EZH2/VASH1 Pathway

Background: Hepatocellular carcinoma is a highly vascularized tumor, so it is critical to study its angiogenesis. Cancer-associated fibroblasts and enhancer of zeste homolog 2 play an important role in tumor angiogenesis and became significant hallmarks of cancer. But the relationship between enhancer of zeste homolog-2 and cancer-associated fibroblasts in response to angiogenesis and its precise mechanism remains unclear. Methods: The separation of cancer-associated fibroblasts was identified by immunofluorescence. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide analysis was used to reveal the proliferation of human umbilical vein endothelial cells. Vascular endothelial growth factor level was quantified by enzyme-linked immunosorbent assay. The wound healing, transwell, and vascular tube formation assays were used to identify the capability of migration, invasion, and tube formation of human umbilical vein endothelial cells in vitro. The detection of tumor angiogenesis was also performed in vivo. Finally, the level of enhancer of zeste homolog-2 and vasohibin 1 were determined by quantitative real-time polymerase chain reaction and Western blotting. Results: In comparison to control and condition medium noncancerous fibroblasts groups, the condition medium cancer-associated fibroblasts could significantly promote the proliferation, migration, invasion, and angiogenesis of human umbilical vein endothelial cells. We found that cancer-associated fibroblasts promoted angiogenesis of human umbilical vein endothelial cells via vascular endothelial growth factor secretion in vitro and in vivo. The upregulation of enhancer of zeste homolog 2 by vascular endothelial growth factor inhibited the expression of vasohibin 1, thus promoting the proliferation and angiogenesis of human umbilical vein endothelial cells. Taken together, the cancer-associated fibroblasts of hepatocellular carcinoma regulate the enhancer of zeste homolog-2/vasohibin 1 pathway via vascular endothelial growth factor secretion, thereby promoting the proliferation and angiogenesis of human umbilical vein endothelial cells. Conclusion: Our study identified the relationship between cancer-associated fibroblasts and enhancer of zeste homolog-2 and confirmed the pivotal role of cancer-associated fibroblasts in angiogenesis of hepatocellular carcinoma. Cancer-associated fibroblasts promote angiogenesis of hepatocellular carcinoma by vascular endothelial growth factor–mediated enhancer of zeste homolog-2/vasohibin 1 pathway and may be a potentially useful therapeutic target for hepatocellular carcinoma.

[1]  Zhou-Ji Zhang,et al.  Down-regulation of KLF5 in cancer-associated fibroblasts inhibit gastric cancer cells progression by CCL5/CCR5 axis , 2017, Cancer biology & therapy.

[2]  Hai Huang,et al.  Anti-angiogenic effect of arsenic trioxide in lung cancer via inhibition of endothelial cell migration, proliferation and tube formation. , 2017, Oncology letters.

[3]  Cun-Yu Wang,et al.  STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4 , 2017, Molecular Cancer.

[4]  X. Fang,et al.  CRH promotes human colon cancer cell proliferation via IL‐6/JAK2/STAT3 signaling pathway and VEGF‐induced tumor angiogenesis , 2017, Molecular carcinogenesis.

[5]  Qinghua Zhou,et al.  Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway , 2017, Oncotarget.

[6]  Yang Zhang,et al.  Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma , 2017, Cancer biology & therapy.

[7]  K. Shirabe,et al.  Cancer-associated fibroblasts in hepatocellular carcinoma. , 2016, World journal of gastroenterology.

[8]  A. Yerlikaya,et al.  Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3. , 2016, Oncology letters.

[9]  S. Zahler,et al.  Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma , 2016, Oncotarget.

[10]  M. Harmsen,et al.  The decrease in histone methyltransferase EZH2 in response to fluid shear stress alters endothelial gene expression and promotes quiescence , 2015, Angiogenesis.

[11]  N. Asai,et al.  Akt-Girdin signaling in cancer-associated fibroblasts contributes to tumor progression. , 2015, Cancer research.

[12]  Yang Zhang,et al.  CD147 promotes Src-dependent activation of Rac1 signaling through STAT3/DOCK8 during the motility of hepatocellular carcinoma cells , 2014, Oncotarget.

[13]  Feipeng Zhao,et al.  EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma , 2014, Oncotarget.

[14]  H. Sasano,et al.  The prognostic significance of vasohibin 1-associated angiogenesis in patients with hepatocellular carcinoma. , 2014, Human pathology.

[15]  W. Oh,et al.  TIMP-1 Promotes Accumulation of Cancer Associated Fibroblasts and Cancer Progression , 2013, PloS one.

[16]  Wei Liu,et al.  Cancer-Associated Fibroblasts from Hepatocellular Carcinoma Promote Malignant Cell Proliferation by HGF Secretion , 2013, PloS one.

[17]  Shou-Jiang Gao,et al.  Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2. , 2012, Cancer research.

[18]  F. Crea,et al.  EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis , 2012, Cancer and Metastasis Reviews.

[19]  Wei Liu,et al.  Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. , 2012, Cancer letters.

[20]  G. Giannelli,et al.  Tumor‐secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts , 2011, Hepatology.

[21]  W. Woodward,et al.  EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. , 2011, Cancer cell.

[22]  G. Calin,et al.  Regulation of tumor angiogenesis by EZH2. , 2010, Cancer cell.

[23]  A. Harris,et al.  Mechanisms of resistance to antiangiogenesis therapy. , 2010, European journal of cancer.

[24]  R. Xiang,et al.  Cancer Associated Fibroblasts Promote Tumor Growth and Metastasis by Modulating the Tumor Immune Microenvironment in a 4T1 Murine Breast Cancer Model , 2009, PloS one.

[25]  Jing Xu,et al.  Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 , 2009, The Journal of experimental medicine.

[26]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[27]  Douglas B. Evans,et al.  Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.

[28]  M. Abe,et al.  Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. , 2004, The Journal of clinical investigation.

[29]  B. Hinz,et al.  Myofibroblasts and mechano-regulation of connective tissue remodelling , 2002, Nature Reviews Molecular Cell Biology.

[30]  M. Makuuchi,et al.  Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. , 1997, Journal of hepatology.